Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Executives On The Move: New Responsibilities For Sanofi CMO, A Strategic Promotion At Alexion And A C-Level Resignation At Medivir
To integrate digital and medical, Sanofi’s CMO Ameet Nathwani is now also Chief Digital Officer. Alexion promotes SVP to Chief Strategy and Business Development Officer, and the CFO resigns from Swedish oncology biotech Medivir.
C-suite moves at cancer biotech Geron Corp, EMD Serono Inc and Kiadis Pharma, while German biotech MorphoSys AG names David Trexler as its new president.
New round of funding allows EdiGene to hire a clinical development executive from Parexel, Teijin Pharma appoints a president, while Astellas has a new president of pharmaceutical technology.
Clinical VPs exit Eisai and Pfizer for positions at mRNA product firm CureVac and nanomedicines developer Taiwan Liposome. New chairman and CEO takes the reins at regenerative medicine company Histogen.
New Year brings a flurry of new executive moves in the life sciences sector in Asia Pacific, including the departure of BeiGene's chief commercial officer and a new chief strategy officer and CMO at Harbour Biomed.
Endologix CEO makes a switch to CEO at Vascular Therapies, and Clinical Research and Commercial VPs exit Gilead Sciences. Plus, producer of OTC and generic drugs Perrigo Company appoints EVP, CSO.
GI head departs Takeda for CMO spot at Ironwood Pharmaceuticals, and global head, oncology leaves Roche for CEO role at Tizona Therapeutics.
Sean Bohen is to join Bahija Jallal, Mark Mallon and Ludovic Helfgott in leaving AstraZeneca as the company transitions to a new organizational structure announced last week by CEO Pascal Soriot.
Elizabeth Barrett becomes the new CEO and President at urology therapy firm UroGen Pharma, and Nimbus Therapeutics promotes financial exec to CFO. Meanwhile, global medical cannabis firm Tilray creates an international advisory board of business and government leaders.
A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.
Executives On The Move: A Duo Of CFOs For Compass And Generation Bio, And At Alcon A Promotion In Japan
Cancer, inflammation and autoimmune firm Compass Therapeutics adds a new CFO, as does gene therapy company Generation Bio. And Alcon Laboratories promotes an exec to region president, Japan.
Executives On The Move: New Hires At EUSA Pharma And Asceneuron, Promotions At Merck And Casma Therapeutics
Bristol Myers-Squibb’s head of discovery joins Foghorn as chief scientific officer, EMD Serono’s head of neurology and immunology joins Cipher, and Merck & Co’s president of global oncology becomes its chief commercial officer.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.